Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Companyâ€™s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	66.73M 46.78M 40.87M 37.81M 35.29M 66.25M 4.42B 449M 175M 2.17B 176M 172M 7.55B	P/E 2027 *	-5.65x	P/E 2028 *	-21.7x
Enterprise Value	51.23M 35.91M 31.38M 29.03M 27.09M 50.86M 3.39B 345M 134M 1.67B 135M 132M 5.8B	EV / Sales 2027 *	-	EV / Sales 2028 *	4.52x
Free-Float	84.81%	Yield 2027 *	-	Yield 2028 *	-

06-22	Amplia Therapeutics Limited Provides Update on Narmafotinib Clinical Progress and Combination Potential with KRAS Inhibitors in Pancreatic Cancer	CI
05-29	Amplia Therapeutics Limited Reports Earnings Results for the Full Year Ended March 31, 2026	CI
05-28	Amplia Therapeutics Limited Auditor Raises 'Going Concern' Doubt	CI
05-19	Amplia Therapeutics Limited Initiates Phase 2B Study of Narmafotinib in Pancreatic Cancer	CI
05-18	Amplia Therapeutics to Start Phase 2B Study of Pancreatic Cancer Drug Candidate	MT
05-10	Amplia Therapeutics Shares Up After Entering Agreement to Conduct Ovarian Cancer Clinical Study	MT
05-08	Amplia Therapeutics Limited And Australia New Zealand Gynaecological Oncology Group Announce Clinical Study Of Narmafotinib In Ovarian Cancer	CI
05-07	Amplia Therapeutics Enters Agreement to Evaluate Lead Drug Candidate in Ovarian Cancer	MT
04-22	Amplia Therapeutics Limited Presents Mature Data from Accent Trial in Pancreatic Cancer	CI
04-08	Amplia Therapeutics Says No Toxicity Concerns Identified Regarding Narmafotinib Drug Candidate After Recruitment Halt in Clinical Trial	MT
04-06	Amplia Therapeutics Puts Trial Recruitment on Hold; Shares Dive 25%	MT
03-23	Amplia Therapeutics Limited Reports Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial	CI
03-23	Amplia Therapeutics reports four additional complete responses and improved overall survival data in Accent pancreatic cancer trial	RE

06-22	Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer	GL
05-19	Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib	GL
05-08	Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study	GL
04-22	Accent Trial Mature Data Presented at International Conference	GL
03-23	Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial	GL

Manager	Title	Age	Since
Christopher J. Burns CEO	Chief Executive Officer	-	2022-12-04
Hamish George DFI	Director of Finance/CFO	-	2021-09-30
Jason Lickliter CTO	Chief Tech/Sci/R&D Officer	-	2025-05-11

Director	Title	Age	Since
Robert Peach BRD	Director/Board Member	70	2015-09-01
Warwick Tong CHM	Chairman	-	2018-05-24
Jane Bell BRD	Director/Board Member	-	2021-04-11

Innate Immunotherapeutics Ltd Stock Australian S.E.

Stocks

AU000000IIL6

Biotechnology & Medical Research

Valuation: Innate Immunotherapeutics Ltd

Latest news : Innate Immunotherapeutics Ltd

Press Releases: Innate Immunotherapeutics Ltd

Quotes and Performance

Managers and Directors: Innate Immunotherapeutics Ltd

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INNATE IMMUNOTHERAPEUTICS LTD	-2.33%	-10.64%	-	-	46.78M
ARGENX SE	+0.38%	+5.66%	+71.37%	+119.88%	56.65B
WUXI APPTEC CO., LTD.	+4.00%	+7.51%	+63.67%	+68.77%	47.49B
BIONTECH SE	-0.77%	-0.67%	-15.34%	-15.95%	22.81B
INSMED INCORPORATED	+2.93%	+1.17%	-3.97%	+384.78%	21.37B
WUXI BIOLOGICS (CAYMAN) INC.	+1.30%	+3.73%	+27.10%	-17.51%	16.12B
GENMAB A/S	+1.62%	+8.16%	+24.39%	-35.71%	15.56B
EXELIXIS, INC.	-1.08%	-3.11%	+27.20%	+158.30%	12.91B
PHARMAESSENTIA CORPORATION	+3.30%	+15.02%	+133.24%	+273.89%	12.86B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.43%	-6.44%	+21.49%	-	11.67B
Average	+1.07%	+2.16%	+38.80%	+117.06%	24.16B
Weighted average by Cap.	+1.59%	+3.27%	+44.90%	+110.05%

	2027 *	2028 *
Net sales	-	10M 7.01M 6.13M 5.67M 5.29M 9.93M 662M 67.33M 26.2M 326M 26.32M 25.75M 1.13B
Net income	-11.6M -8.13M -7.11M -6.57M -6.13M -11.52M -768M -78.1M -30.39M -378M -30.53M -29.87M -1.31B	-3.6M -2.52M -2.21M -2.04M -1.9M -3.57M -238M -24.24M -9.43M -117M -9.47M -9.27M -407M
Net Debt	-15.5M -10.86M -9.49M -8.78M -8.2M -15.39M -1.03B -104M -40.6M -505M -40.79M -39.91M -1.75B	-21.5M -15.07M -13.17M -12.18M -11.37M -21.34M -1.42B -145M -56.32M -700M -56.58M -55.36M -2.43B